التداول الداخلي في الأسهم الأمريكية | أعلنت شركة Repligen في 5 مارس عن صفقتي تداول داخلي من قبل كبار المسؤولين في الشركة

5 March 2026, Repligen (RGEN) disclosed two company insider trades. Executive Bylund James sold 62 shares on 4 March 2026.

【Recent Insider Trading】

【Company Profile】

Repligen Corporation is a leading provider of key products for biopharmaceutical manufacturing. The company’s protein A produced provides long-term supply and long-term contracts to important life science research companies, and also sells directly to the end users in the pharmaceutical processing chain. The company provides professional bioresearch products to SecreFlo’s latest drugs. These drugs have already been submitted to the U.S. Food and Drug Administration and have been granted priority review, and the company has submitted market authorization licensing to the European medicine regulatory authorities. SecreFlo is a company developing a novel imaging agent as a synthetic human hormone drug for diagnosing pancreatitis and multiple potential pancreatic diseases. The company is conducting research on two early-stage rare central nervous system disease programs—Friedreich’s ataxia and spinal muscular atrophy—entering Phase 1 of clinical trials. In addition, the company has obtained an additional license for intellectual property from Bristol-Myers Squibb—this company can hold the patent rights to sell the drug Abacuspir in the U.S. through its patent rights. The company was founded in May 1981.